华东医药：芮妥欣®铺货推进符合前期规划

证券之星07-01

证券之星消息，华东医药(000963)07月01日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘您好。芮妥欣作为公司重点医美产品，自上市以来市场关注度较高。想了解目前该产品的全国渠道覆盖与铺货推进节奏是否符合既定规划？终端合作机构的动销反馈及市场接受度如何？公司针对该产品的后续学术推广与市场布局有怎样的安排？感谢解答。

华东医药回复：您好！芮妥欣铺货推进符合前期规划，依托成熟医美渠道已快速覆盖全国主流连锁医美机构，下半年将逐步放量。终端机构对其重组技术差异化优势认可度高，用户口碑稳步提升。后续公司将持续开展全国专家学术会、规范化实操培训，持续夯实产品学术壁垒，协同全品类医美矩阵扩大市场覆盖。感谢您的关注！

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

相关 ETF

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2648515126?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-01 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648515126","market":"sh","top_or_hot":-1,"title":"华东医药：芮妥欣®铺货推进符合前期规划","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/000963\">华东医药</a>(000963)07月01日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘您好。芮妥欣作为公司重点医美产品，自上市以来市场关注度较高。想了解目前该产品的全国渠道覆盖与铺货推进节奏是否符合既定规划？终端合作机构的动销反馈及市场接受度如何？公司针对该产品的后续学术推广与市场布局有怎样的安排？感谢解答。</p><p>华东医药回复：您好！芮妥欣铺货推进符合前期规划，依托成熟医美渠道已快速覆盖全国主流连锁医美机构，下半年将逐步放量。终端机构对其重组技术差异化优势认可度高，用户口碑稳步提升。后续公司将持续开展全国专家学术会、规范化实操培训，持续夯实产品学术壁垒，协同全品类医美<a href=\"https://laohu8.com/S/301365\">矩阵</a>扩大市场覆盖。感谢您的关注！</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/15936120260630.png\"/><img src=\"https://static.stockstar.com/etf/58827020260630.png\"/><img src=\"https://static.stockstar.com/etf/15978120260630.png\"/><img src=\"https://static.stockstar.com/etf/51608020260630.png\"/></p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华东医药：芮妥欣®铺货推进符合前期规划</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华东医药：芮妥欣®铺货推进符合前期规划\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-01 16:24 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026070100030658.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，华东医药(000963)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好。芮妥欣作为公司重点医美产品，自上市以来市场关注度较高。想了解目前该产品的全国渠道覆盖与铺货推进节奏是否符合既定规划？终端合作机构的动销反馈及市场接受度如何？公司针对该产品的后续学术推广与市场布局有怎样的安排？感谢解答。华东医药回复：您好！芮妥欣铺货推进符合前期规划，依托成熟医美渠道已快速...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026070100030658.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000963","symbol_name":"华东医药","start_time":0,"source_url":"https://stock.stockstar.com/RB2026070100030658.shtml","article_id":"2648515126","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648515126","pubTimestamp":1782894254,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，华东医药07月01日在投资者关系平台上答复投资者关心的问题。芮妥欣作为公司重点医美产品，自上市以来市场关注度较高。芮妥欣铺货推进符合前期规划，依托成熟医美渠道已快速覆盖全国主流连锁医美机构，下半年将逐步放量。终端机构对其重组技术差异化优势认可度高，用户口碑稳步提升。后续公司将持续开展全国专家学术会、规范化实操培训，持续夯实产品学术壁垒，协同全品类医美矩阵扩大市场覆盖。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"000963":"华东医药","BK0209":"零售","BK0183":"MSCI概念","BK0132":"高送转概念","BK0188":"融资融券","BK0196":"行业龙头","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0175":"白马股","BK0187":"一线龙头"},"translate_title":"Huadong Medicine: Ruituoxin ® Promotion of distribution is in line with the early planning","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":1.5},"content_text":"证券之星消息，华东医药(000963)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好。芮妥欣作为公司重点医美产品，自上市以来市场关注度较高。想了解目前该产品的全国渠道覆盖与铺货推进节奏是否符合既定规划？终端合作机构的动销反馈及市场接受度如何？公司针对该产品的后续学术推广与市场布局有怎样的安排？感谢解答。华东医药回复：您好！芮妥欣铺货推进符合前期规划，依托成熟医美渠道已快速覆盖全国主流连锁医美机构，下半年将逐步放量。终端机构对其重组技术差异化优势认可度高，用户口碑稳步提升。后续公司将持续开展全国专家学术会、规范化实操培训，持续夯实产品学术壁垒，协同全品类医美矩阵扩大市场覆盖。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648515126","isCrawlerRequest":true}